Product information and disease descriptionProduct descriptionProduct information
Special populations
5 evidence topics · 5 sources
Age: adults in the phase 2b trial
“MG-001 part 3 was a prospective, double-blind, multicenter, randomized placebo-controlled phase 2b trial evaluating the safety and clinical activity of Descartes-08, RNA-engineered anti-BCMA CAR-T, in adults with generalized MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric population: HELIOS trial including juvenile myasthenia gravis
Contraception for women of childbearing potential in AURORA
Male contraception in the phase 2b trial
“Male patients were to agree to effective contraception (for example, condoms (male or female) with or without a spermicidal agent, a diaphragm or cervical cap with spermicide, or an intrauterine device) from screening through 14 days after the last dose of Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote